Literature DB >> 16251323

Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.

Marçal Mariné1, Carolina Serena, Belkys Fernández-Torres, F Javier Pastor, Josep Guarro.   

Abstract

We compared the efficacies of amphotericin B, fluconazole, flucytosine, and micafungin in a systemic murine infection by three isolates of Candida glabrata. Amphotericin B showed the best results, although none of the drugs dramatically reduced mortality or tissue burden in liver or spleen.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16251323      PMCID： PMC1280170          DOI： 10.1128/AAC.49.11.4757-4759.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Efficacy of micafungin alone or in combination against systemic murine aspergillosis.

Authors:  Javier Capilla Luque; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 2.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

3.  In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.

Authors:  Manuel Cuenca-Estrella; Dolores Rodriguez; Benito Almirante; Juliette Morgan; Ana Maria Planes; Manel Almela; José Mensa; Ferran Sanchez; Josefina Ayats; Montserrat Gimenez; Margarita Salvado; David W Warnock; Albert Pahissa; Juan L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2004-12-23       Impact factor: 5.790

4.  Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  C Viscoli; C Girmenia; A Marinus; L Collette; P Martino; B Vandercam; C Doyen; B Lebeau; D Spence; V Krcmery; B De Pauw; F Meunier
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

5.  Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei.

Authors:  M A Fisher; S H Shen; J Haddad; W F Tarry
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans.

Authors:  Montserrat Ortoneda; Javier Capilla; Isabel Pujol; F Javier Pastor; Emilio Mayayo; Joan Fernández-Ballart; Josep Guarro
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

7.  Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice.

Authors:  Justina Y Ju; Cynthia Polhamus; Kieren A Marr; Steven M Holland; John E Bennett
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

8.  Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

Authors:  D J Diekema; S A Messer; A B Brueggemann; S L Coffman; G V Doern; L A Herwaldt; M A Pfaller
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

9.  Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice.

Authors:  B A Atkinson; C Bouthet; R Bocanegra; A Correa; M F Luther; J R Graybill
Journal:  J Antimicrob Chemother       Date:  1995-05       Impact factor: 5.790

10.  Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis.

Authors:  Montserrat Ortoneda; Javier Capilla; Francisco J Pastor; Isabel Pujol; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191
View more
  5 in total

1.  In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Authors:  Susanne Perkhofer; Cornelia Mrazek; Lukas Hartl; Cornelia Lass-Flörl
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

2.  Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy.

Authors:  Marçal Mariné; F Javier Pastor; Ismail H Sahand; José Pontón; Guillermo Quindós; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

3.  Efficacy of triazoles in a murine disseminated infection by Candida krusei.

Authors:  Marçal Mariné; F Javier Pastor; Carolina Serena; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

Review 4.  Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections.

Authors:  Frederic Lamoth; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2020-12-30

5.  Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence.

Authors:  Sélène Ferrari; Françoise Ischer; David Calabrese; Brunella Posteraro; Maurizio Sanguinetti; Giovanni Fadda; Bettina Rohde; Christopher Bauser; Oliver Bader; Dominique Sanglard
Journal:  PLoS Pathog       Date:  2009-01-16       Impact factor: 6.823
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.